>
Sunday FULL SHOW: Newly Released & Verified Epstein Files Confirm Globalists Engaged...
Fans Bash Bad Bunny's 'Boring' Super Bowl Halftime Show, Slam Spanish Language Performan
Trump Admin Refuses To Comply With Immigration Court Order
U.S. Government Takes Control of $400M in Bitcoin, Assets Tied to Helix Mixer
SpaceX Authorized to Increase High Speed Internet Download Speeds 5X Through 2026
Space AI is the Key to the Technological Singularity
Velocitor X-1 eVTOL could be beating the traffic in just a year
Starlink smasher? China claims world's best high-powered microwave weapon
Wood scraps turn 'useless' desert sand into concrete
Let's Do a Detailed Review of Zorin -- Is This Good for Ex-Windows Users?
The World's First Sodium-Ion Battery EV Is A Winter Range Monster
China's CATL 5C Battery Breakthrough will Make Most Combustion Engine Vehicles OBSOLETE
Study Shows Vaporizing E-Waste Makes it Easy to Recover Precious Metals at 13-Times Lower Costs

The groundbreaking method may prove useful in treating myriad malignancies, inflammatory diseases and rare genetic disorders.
Lipid nanoparticles (LNP) were used to deliver modified messenger RNA to treat inflammatory bowel diseases and other diseases.
Prof. Dan Peer, Molecular Cell Biology at TAU's Faculty of Life Sciences, led the research for the new study.
Over the past few years, lipid carriers encapsulating messenger RNAs (mRNAs) have been shown to be extremely useful in altering the protein expressions for a host of diseases. But directing this information to specific cells has remained a major challenge.
"In our new research, we utilized mRNA-loaded carriers — nanovehicles carrying a set of genetic instructions via a biological platform called ASSET — to target the genetic instructions of an anti-inflammatory protein in immune cells," says Prof. Peer.